Inclisiran prescribed to 7% of expected target population in three years, NHS data reveal
Exclusive: The Royal College of General Practitioners and the British Medical Association maintain that caution should be taken when prescribing inclisiran since long-term trial data on the drug will not be available until 2026.
Between October 2021 and October 2024, 19,416 people were prescribed inclisiran in primary care in England, according to the NHS Business Services Authority
Shutterstock.com
Fewer than 20,000 people in England have been prescribed anticholesterol drug inclisiran (Leqvio; Novartis) in primary care since 2021, despite expectations set by the NHS that 300,000 people would be taking the drug by 2024.
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.